Elevation Oncology, Inc.
NASDAQ Global SelectTotal Valuation
Elevation Oncology, Inc. carries a market capitalization of 21.63M, placing it among publicly traded companies globally. Its enterprise value stands at -34.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.63M |
| Enterprise Value | -34.09M |
Share Statistics
Elevation Oncology, Inc. currently has 59.22M shares outstanding.
| Shares Outstanding | 59.22M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.06 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | -0.39 |
| P/OCF Ratio | -0.39 |
Financial Position
Elevation Oncology, Inc. maintains a current ratio of 19.40, meaning it holds 19.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 19.40 |
| Quick Ratio | 19.04 |
| Debt / Equity | 66.87 |
| Debt / EBITDA | -0.68 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 38,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Elevation Oncology, Inc.'s stock has declined approximately -54.375% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 0.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -54.375% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.49 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -45.66M, while operating income came in at -45.67M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -45.67M |
| Pretax Income | -47.95M |
| Net Income | -47.99M |
| EBITDA | -45.66M |
| EBIT | -45.67M |
| Earnings Per Share (EPS) | -0.81 |
Balance Sheet
Elevation Oncology, Inc. holds 80.66M in cash and equivalents against 31.25M in total debt, resulting in a net debt position of -29.24M. Total book value stands at -254.66M, with working capital of 77.96M providing operational flexibility.
| Cash & Cash Equivalents | 80.66M |
| Total Debt | 31.25M |
| Net Debt | -29.24M |
| Equity (Book Value) | -254.66M |
| Book Value Per Share | -4.31 |
| Working Capital | 77.96M |
Cash Flow
Elevation Oncology, Inc. produced -39.50M in operating cash flow over the past twelve months.
| Operating Cash Flow | -39.50M |
| Capital Expenditures | N/A |
| Free Cash Flow | -39.50M |
| FCF Per Share | -0.67 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -95.80 |
| FCF Yield | -257.93 |
Scores
Elevation Oncology, Inc. posts an Altman Z-Score of -4.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.77 |